Sacituzumab Govitecan In TNBC
Conditions: Invasive Breast Cancer; Triple Negative Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; HER2-negative Breast Cancer Intervention: Drug: Sacituzumab Govitecan Sponsors: Aditya Bardia; Immunomedics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials